Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-02-10

Clinical Trial Update: Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of evinacumab (REGN1500) in participants with persistent hypercholesterolemia has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Evinacumab (evinacumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2023-02-10